The Future of Psychedelics with Dr. Matthew Johnson

In this interview, Don MacPherson is joined by Dr. Matthew Johnson, an expert in psychoactive drug effects, addiction, and risk behavior. They discuss clinical research on psychedelics including psilocybin, ayahuasca, DMT, MDMA, LSD, and more. They also dive into the potential therapeutic applications for psychedelics including treating depression, PTSD, and addiction, and improving individual happiness, creativity, and selflessness.

Matthew W. Johnson, Ph.D., Professor at Johns Hopkins, is an expert in psychoactive drug effects, addiction, and risk behavior. He has worked with psychedelics since 2004. He developed and published the first psychedelic treatment of tobacco addiction in 2014. With colleagues, he conducted and published the largest study of psilocybin in cancer distress in 2016. He is Principal Investigator on upcoming psilocybin studies treating opioid addiction and PTSD, and LSD research treating chronic pain.